Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1

BACKGROUND: Interferon-free regimens to treat hepatitis C virus (HCV) genotype 1 are effective but costly. At this time, payers in the United States use strategies to control costs including (1) limiting treatment to those with advanced disease and (2) negotiating price discounts in exchange for exc...

Descripción completa

Detalles Bibliográficos
Autores principales: Linas, Benjamin P., Morgan, Jake R., Pho, Mai T., Leff, Jared A., Schackman, Bruce R., Horsburgh, C. Robert, Assoumou, Sabrina A., Salomon, Joshua A., Weinstein, Milton C., Freedberg, Kenneth A., Kim, Arthur Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414108/
https://www.ncbi.nlm.nih.gov/pubmed/28480259
http://dx.doi.org/10.1093/ofid/ofw266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414108/
https://www.ncbi.nlm.nih.gov/pubmed/28480259
http://dx.doi.org/10.1093/ofid/ofw266

Ejemplares similares